NASDAQ: VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
After hours: $479.00(0%) · as of 5:46 PM ET
Market Cap
$121.57B
52w High
$533.67
52w Low
$362.50
P/E
28.30
Volume
1.62M
Outstanding Shares
253.81M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 3.94% over the last year. Revenue grew 10.41% over the trailing twelve months. Operating margin moved from -6.69% to 38.97%. Free cash flow grew 394.94% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 38.97%. A decisive move in revenue — currently up 10.41% — would be the clearest signal to resolve the ambiguity.
Company profile
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF).
Valuation
Stock splits
Every 1 shares became 2
Profitability & growth
Analyst consensus
48
Buy
7
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est $4.74 · Revenue est $3.23B
View